News

NHF Applauds Congressional Enactment of The Hemophilia SNF Access Act

Industry News & Research, Living with a Bleeding Disorder

The National Hemophilia Foundation is thrilled to announce that its top legislative priority in 2020, The Hemophilia SNF Access Act. The National…

Read More

State of Denial: Tips on How to Work with Your Insurance Provider When You are Denied Coverage for Services or Medications

Health and Well Being, Industry News & Research, Living with a Bleeding Disorder

by: Laurie Kelley When you submit an insurance form for coverage, have you ever been denied?   What should you do if you’ve already…

Read More

National Hemophilia Foundation and Hemophilia Federation of America Partner for “Together Project”

Advocacy & Legislation, Industry News & Research

New partnership kicks off with a focus on mental health. The National Hemophilia Foundation (NHF) joins the Hemophilia Federation of America (HFA)…

Read More

CDC Public Health Webinar on NHF Guidelines

Industry News & Research

Healthcare professionals, register now for February CDC webinar on new NHF-McMaster hemophilia care guidelines. NHF is excited to announce that the Centers for…

Read More

NHF Responds to STIMATE® Production Update

Industry News & Research

CSL Behring announced that the company’s distribution agreement with Ferring Pharmaceuticals for STIMATE® nasal spray recently expired and will not be renewed…

Read More

Prophylaxis Indication Restored for BeneFIX®

Industry News & Research

Prophylaxis Indication Restored for BeneFIX® Sep 14, 2021 In February 2021, the U.S. Food and Drug Administration (FDA) partially rescinded a supplemental Biologics…

Read More

Vector Biology and Hemophilia Gene Therapy the Focus of Review

Industry News & Research

A new review article, The Intersection of Vector Biology, Gene Therapy and Hemophilia, was published recently in the journal Research Practice in…

Read More

Read New COVID-19 FAQs

COVID-19

NHF recently updated its COVID-19 FAQ web page. See the latest community questions and guidance and share with others who might be…

Read More

Medicaid 101: Why Medicaid is Important to the Bleeding Disorders Community

Advocacy & Legislation, Industry News & Research

With Medicaid much in the news in August, it seemed timely to offer a refresher on how Medicaid is structured, and why…

Read More

Learn More About the Latest in Gene Therapy: FAQ’s, Clinical Trials and Scientific Research

Industry News & Research, Living with a Bleeding Disorder

The National Hemophilia Foundation (NHF) heard a lot of questions from the community about gene therapy clinical trials for hemophilia at its…

Read More

Cardinal Health announces a voluntary recall for select Monoject™ Flush Prefilled Saline Syringes

Industry News & Research

News on a recent FDA recall affecting the inheritable blood disorder community. NHF requests members of the inheritable blood disorders community be…

Read More

Camp Klotty Pine Focused on Health and Friendships – And It Was Just What Camper’s Needed!

GLHF News

At Camp Klotty Pine, GLHF helps kids become more independent, learn about their bleeding disorder and take control of their care. Camp is…

Read More

New Nursing Guidelines Available on Administration of Bleeding Disorders Therapies

Industry News & Research

These guidelines are readily accessible in PDF format on the NHF website. NHF is pleased to announce that two new resources have…

Read More

Living with Bleeding Disorders in the Time of COVID

COVID-19, Living with a Bleeding Disorder

by: Sari Harrar Pandemic stories of strength, perseverance and resiliency from three members of the bleeding disorders community. The COVID-19 pandemic has…

Read More

TARPA-H Overview

Industry News & Research

President Biden has called for the creation of a new $6.5 billion research institute, the Advanced Research Projects Agency for Health (ARPA-H),…

Read More

Four Decades of HIV

Health and Well Being, Industry News & Research, Living with a Bleeding Disorder

This past June marked a significant milestone for the bleeding disorders community. Forty years ago, on June 5, 1981, the CDC first…

Read More

COVID-19: Health and Wellness Update from NHF’s Dr. Leonard Valentino

COVID-19, Industry News & Research

The cautious optimism of May and June with regards to emerging from the pandemic has shifted as we are witnessing a resurgence…

Read More

Spark Provides Trial Updates for Investigational Gene Therapy SPK-8011

Industry News & Research

SPK-8011 is Spark Therapeutics’ investigational gene therapy candidate for hemophilia A. Spark Therapeutics recently announced updates from an ongoing phase 1/2 clinical…

Read More

New Descriptive Study Looks at Bleeding Disorder Camps

Industry News & Research

The study included a number of notable findings relevant to the participation of healthcare providers in bleeding disorder camps (BDCs), adherence to…

Read More

NHF Responds to New CMS Guidance

Industry News & Research

New guidance from the U.S. Department of Health and Human Services encourages states to educate eligible immigrants about Medicaid coverage. In a…

Read More

BioMarin Hemophilia A Clinical Development Program: An Update for the Hemophilia Community

Industry News & Research

BioMarin is pleased to update the community regarding our ongoing gene therapy clinical trial program in hemophilia A. BioMarin’s investigational gene therapy…

Read More

Review Your Health Coverage: Recent Federal Law Lowers Costs, Opens Up New Options

Advocacy & Legislation, Industry News & Research

The American Rescue Plan (ARP), signed into law on March 11, 2021, provides new opportunities to get health insurance coverage, and/or to…

Read More

New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A

Industry News & Research

Final analysis from the Phase IIIb STASEY study, including data from 193 people with hemophilia A, further support the benefit/risk profile of…

Read More

FDA Places Clinical Hold on Sigilon’s Investigational Hemophilia Therapy

Industry News & Research

Sigilon’s cell-based therapy is designed to carry significant amounts of synthetic DNA material to elicit the production of factor VIII in individuals…

Read More